back pain from semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease Over 30 million Americans are

Where do you go for help

How do I enable JavaScript

Eli Lilly and Company is the pharmaceutical company that makes two tirzepatide products that are approved by the Food and Drug Administration (FDA): Mounjaro, which is approved by the FDA for improving blood sugar levels in people with Type 2 diabetes, and is often prescribed off-label for weight loss Zepbound, which is FDA approved for weight loss, as well as for obstructive sleep apnea in adults with obesity Currently, there are no FDA-approved generic versions of the drugs Mounjaro or Zepbound, and there are not any other FDA-approved tirzepatide products available besides brand-name Mounjaro and Zepbound

Potency matters because too little active ingredient means reduced efficacy, while too much can cause excessive side effects

Supporting GLP-1 function naturally allows the body to regulate appetite, energy and metabolic efficiency in a sustainable way

The hepatic safety profile of approved weight loss injections appears favourable overall, with potential benefits outweighing risks for most patients